Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

May 27, 2025 — Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link ...

“People with psoriasis that is severe enough to require pills, phototherapy, or biologics have a five-year reduction in life expectancy, the majority of which is due to excess risk of ...

The approvals add two more options for psoriasis patients hoping to stay away from biologics as long as they can. If symptoms remain mild to moderate, patients can stay on these drugs indefinitely.

MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and ...

J&J is hoping to show that the peptide drug can be a more patient-friendly alternative to injectable biologics for plaque psoriasis, including drugs working on IL-23, such as J&J's own Tremfya ...

If you have psoriasis, you may feel like this autoimmune disease is plenty to cope with all on its own. But unfortunately there are a number of other health issues linked to the condition.